Could a blood thinner and heart pill prevent deadly liver complications?
NCT ID NCT07521332
First seen Apr 17, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This study tests whether adding the blood thinner apixaban to the heart drug carvedilol can prevent complications like bleeding, fluid buildup, and confusion in people with cirrhosis and high blood pressure in the liver. About 220 adults with stable cirrhosis will take either apixaban plus carvedilol or a placebo plus carvedilol for 12 months. Researchers will track how many develop serious liver-related events and monitor bleeding risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asian Institute of Medical Sciences
RECRUITINGHyderābād, Sindh, 71000, Pakistan
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Apixaban and carvedilol
What this could lead to
If it works, this combination could reduce serious complications like variceal bleeding and fluid buildup in people with cirrhosis.
What could go wrong
This is a single-blind, phase 4 trial in one hospital in Pakistan, so results may not apply broadly. Apixaban also raises bleeding risk, which is especially dangerous in liver disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.